US/UK/Canada

Share

Contacts

  • Cyxone AB
    Hyllie Boulevard 34, 215 32 Malmö, Sweden
    +46 708882172
    +46 708882172
    https://cyxone.com/en/

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -
    Tags ( Active)

    The subscription period in Cyxone’s rights issue starts today

    Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the "Rights Issue") of a maximum of SEK 23 million, with preferential right for the Company's existing shareholders, begins. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa inhibitors and to finance development of T20K. The subscription period runs until 15 August 2024. A memorandum is available via the Company's (www.cyxone.com) website.NOT FOR

    Cyxone AB publishes investment memorandum

    On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of shares (the "Rights Issue"). Prior to the Rights Issue, Cyxone has prepared an investment memorandum containing information about the Company and the Rights Issue, which is now available via the Company's website (www.cyxone.com). The subscription period begins on 1 August 2024 and lasts until 15 August 2024.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND,

    The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K

    The board of Cyxone AB (publ), corporate no. 559020-5471, ("Cyxone" or the "Company") has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders for a total of approximately SEK 23 million before deductions for transaction costs (the "Rights Issue"). The decision has been made with the support of authorization from the annual general meeting in 2024. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa

    Cyxone provides an update on its research and development program

    Cyxone (publ) is a biotech company with two promising clinical stage drug candidates, rabeximod and T20K, for autoimmune diseases. The company announces an updated development plan that aligns with the revised strategy revealed in August 2023, aiming to bring hope to patients suffering from these conditions.In April of this year, Kjell Stenberg, a seasoned leader in the biotech industry, was appointed as the company's new CEO. In collaboration with an external team of key opinion leaders and an internal team, Dr. Stenberg reviewed the latest findings for both the rabeximod and T20K projects.

    Cyxone enters important research collaboration

    Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged research group at University of Glasgow, UK, with the objective of performing an exploratory phase 2 study with rabeximod in patients with rheumatoid arthritis (RA).https://cyxone.com/en/The research group at School of Infection and Immunity, University of Glasgow is an internationally recognised centre of excellence conducting high quality basic, translational and clinical research in the disciplines of infection, immunology and inflammation. The

    Cyxone reaches important milestone regarding mechanism of action

    Cyxone (publ), a biotech company in autoimmune diseases, has reached an important milestone for the drug candidate rabeximod. Recently, the biological target protein for rabeximod was identified, a finding that has now been confirmed in an independent scientific analysis. This important milestone represents a major step forward for the project as the new knowledge contributes to an increased understanding of the drug's mechanism of action and confirms its First-in-Class status.Rabeximod is an immunomodulatory drug that has shown selectivity for pro-inflammatory macrophages and dendritic

    Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

    Cyxone (publ), a biotech company in autoimmune diseases, re-engages Professor Rikard Holmdahl as Scientific Advisor for the company’s projects in autoimmune diseases.Rikard Holmdahl has long established experience and expert knowledge in immunology and autoimmune diseases. Professor Holmdahl is one of Sweden’s leading scientists in immunology who has contributed to very valuable insights into the mechanisms causing chronic inflammatory diseases such as multiple sclerosis and rheumatoid arthritis. He has during his career been acknowledged with several prestigious scientific prizes for his

    Cyxone revises strategy for commercial alignment targeting valuable market opportunities

    Cyxone (publ), a biotech company in autoimmune diseases, with its lead asset rabeximod under development in rheumatoid arthritis, is revising its previous strategy due to important patent grants and valuable market opportunities.During 2023 a range of new biosimilar disease modifying anti-rheumatic drugs (DMARDs), approved by the US Food and Drug Administration, FDA, have been broadly introduced to the American market. As a result, patients with moderate to severe rheumatoid arthritis that have inadequate response to methotrexate will now be offered a range of less costly TNFa inhibitor

    Cyxone receives patent approval from the US for the salt forms of the compound rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has obtained granted status for the US patent application 17/891,462 entitled Rabeximod Compounds from the United States Patent and Trademark Office (USPTO).The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042. ”We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and

    Cyxone receives Notice of Allowance from the US Patent Office for the protection of Rabeximod compound

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 17/891,462 entitled Rabeximod Compounds. The application covers the protection of salt forms of the compound Rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent.

    Cyxone makes significant progress in the manufacturing process for Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, has in collaboration with its contract development and manufacturing organization (CDMO) managed to significantly streamline part of the manufacturing process of the drug candidate Rabeximod, which is under development for the treatment of rheumatoid arthritis (RA).As part of the continued development of Rabeximod, Cyxone is now, in collaboration with its CDMO, working on the development of creating a scalable manufacturing process for the late development phases as well as the commercialization of Rabeximod. Rabeximod is produced by

    Cyxone receive ethical and regulatory approval from Georgia to conduct clinical Phase 2b study in RA

    Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (LEPL regulation Agency for Medical and Pharmaceutical Activities) and local Ethics Committees in Georgia to conduct a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with

    Cyxone advances the patent portfolio for Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041.In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone today reports the

    Cyxone receive ethical and regulatory approval from Hungary to start clinical Phase 2b study in RA

    Cyxone (publ), a biotech company in autoimmune diseases, have received approval from the Hungarian Central Ethics Committee and the Medical Product Agency - National Institute of Pharmacy and Nutrition (OGYEI) to start a clinical Phase 2b study - APPRAIS - with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with

    Cyxone receive regulatory approval to start clinical Phase 2b study in RA

    Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).“The approval is a very important milestone for us. Cyxone have now finally the possibility to initiate the greatest and foremost value-building activity ever in the company’s history. Receiving this green light from Poland,

    Cyxone files submission to start clinical Phase 2b study in Poland and Georgia

    Cyxone (publ), a biotech company in autoimmune diseases, have now filed submissions to the Office for Registration of Medicinal Products, Medical devices and Biocides and the Central Ethics Committee in Poland as well as at local Ethics Committees in Georgia for approval to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).The submissions to the Regulatory Authorities and the responsible Ethical Committees in Poland and Georgia for approval to start a clinical phase 2b trial with Cyxone’s drug candidate

    Cyxone receives pre-IND response from the US FDA regarding RA study

    Cyxone (publ), a biotech company in autoimmune diseases, has received a response from a Type B pre-IND meeting with the US Food and Drug Administration (FDA) regarding the upcoming study with the drug candidate Rabeximod, which is in development as a treatment for rheumatoid arthritis (RA).“We are pleased to now have received a written response from the pre-IND interaction we have had with the FDA and as expected they provided very valuable advice both regarding our preclinical and clinical development activities which ensure a continued adequate way forward for Rabeximod in RA. The FDA is

    Cyxone files regulatory submission to start clinical phase 2b study with Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, today filed a submission to the National Institute of Pharmacy and Nutrition (OGYEI) - the Hungarian Medical Product Agency - for approval to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). This first submission will be followed by applications to relevant regulatory authorities in other European countries.The submission to the Hungarian Regulatory Authority OGYEI for approval to start a clinical phase 2b trial with Cyxone’s drug candidate

    Cyxone announces forward looking drug development strategy with focus on Rabeximod in Rheumatoid Arthritis trial

    Cyxone AB (CYXO), a clinical-stage company developing transformative therapies in the autoimmune area to improve patient outcomes, today provided a forward-looking strategy.Rabeximod in Rheumatoid Arthritis Rheumatoid arthritis (RA) is chronic disease, affecting more than 20 million patients globally, that require convenient rest-of-the-life treatment with as few side-effects and drug interactions as possible. There is still a large unmet need for new oral therapies with novel modes of action to give rheumatologists real alternatives to current therapies. Over 40% of patients don’t

    Safety confirmation and observed trends in Covid-19 study build further confidence in Cyxone’s rheumatoid arthritis program

    Cyxone AB (publ), the Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis (RA) confirms the previously demonstrated favorable safety and tolerability profile for its drug candidate Rabeximod, in the Clinical Study Report from its exploratory phase 2 study in Covid-19 patients. Other observations include a trend showing patients that were given Rabeximod, in comparison to the placebo group, had a higher rate of early release from the hospital. Exploratory endpoints analysis indicated modulation of disease relevant cytokine biomarkers by

    Cyxone step up activities and extend collaboration with global CRO around RA trial

    Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical contract research organization (CRO) following on an early operations agreement (EOA) signed last month. The LOA is a key step for advancing the clinical phase 2b trial of Rabeximod in patients with rheumatoid arthritisThe agreement enables Cyxone to expand and intensify start-up activities for the phase 2b trial including site selections and regulatory submissions enabling an efficient route to enrolling patients into the trial within the shortest period of time.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media